[go: up one dir, main page]

AU2001251115A1 - Use of locally applied dna fragments - Google Patents

Use of locally applied dna fragments

Info

Publication number
AU2001251115A1
AU2001251115A1 AU2001251115A AU5111501A AU2001251115A1 AU 2001251115 A1 AU2001251115 A1 AU 2001251115A1 AU 2001251115 A AU2001251115 A AU 2001251115A AU 5111501 A AU5111501 A AU 5111501A AU 2001251115 A1 AU2001251115 A1 AU 2001251115A1
Authority
AU
Australia
Prior art keywords
dna fragments
locally applied
applied dna
locally
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001251115A
Inventor
Mark Eller
Barbara A Gilchrest
Mina Yaar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/540,843 external-priority patent/US7094766B1/en
Application filed by Boston University filed Critical Boston University
Publication of AU2001251115A1 publication Critical patent/AU2001251115A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001251115A 2000-03-31 2001-03-30 Use of locally applied dna fragments Abandoned AU2001251115A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/540,843 US7094766B1 (en) 1995-06-06 2000-03-31 Use of locally applied DNA fragments
US09540843 2000-03-31
PCT/US2001/010162 WO2001074342A2 (en) 2000-03-31 2001-03-30 Use of locally applied dna fragments

Publications (1)

Publication Number Publication Date
AU2001251115A1 true AU2001251115A1 (en) 2001-10-15

Family

ID=24157158

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001251115A Abandoned AU2001251115A1 (en) 2000-03-31 2001-03-30 Use of locally applied dna fragments

Country Status (5)

Country Link
US (2) US7033829B2 (en)
EP (2) EP2363133A1 (en)
AU (1) AU2001251115A1 (en)
HK (1) HK1054184A1 (en)
WO (1) WO2001074342A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
AU2001262108A1 (en) * 2000-03-17 2001-09-24 Unilever Plc Non-physiologic dna fragments for tanning skin
AU2001251115A1 (en) * 2000-03-31 2001-10-15 Trustees Of Boston University Use of locally applied dna fragments
US20040052840A1 (en) * 2000-06-20 2004-03-18 Shunichiro Kubota Preparations for oligonucleotide transfer
KR100888566B1 (en) * 2001-06-20 2009-03-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 How to Promote Nucleic Acid Introduction
US20080318319A1 (en) * 2003-12-19 2008-12-25 Yoshiko Minakuchi Novel Method of Nucleic Acid Transfer
DE602005012948D1 (en) 2004-05-06 2009-04-09 Us Gov Health & Human Serv METHOD AND COMPOSITIONS FOR TREATING UVEITIS
EP1761629A2 (en) * 2004-05-19 2007-03-14 Trustees Of Boston University Modulation of wrn-mediated telomere-initiated cell signaling
BG65639B1 (en) * 2004-06-25 2009-04-30 Диана СТЕФАНОВА Regeneration composition
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
US20100286247A1 (en) * 2005-04-04 2010-11-11 Trustees Of Boston University Methods of Protection from Oxidative Stress
PL3329004T3 (en) 2015-07-29 2020-10-05 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Therapeutic oligonucleotides
EP3124609A1 (en) 2015-07-29 2017-02-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutics oligonucleotides

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937809A (en) 1974-05-01 1976-02-10 Kolmar Laboratories, Inc. Addition compound of a nucleotide and an amino acid and the use thereof in protection against actinic radiation
FR2439013A1 (en) 1978-10-19 1980-05-16 Serobiologiques Lab Sa COMPOSITION FOR USE IN PARTICULAR AS A COSMETIC PRODUCT FOR TANNING THE SKIN, INCLUDING THE USE OF AMINO ACIDS
CA1200773A (en) 1980-02-29 1986-02-18 William J. Rutter Expression linkers
FR2521565B1 (en) 1982-02-17 1985-07-05 Dior Sa Parfums Christian PULVERULENT MIXTURE OF LIPID COMPONENTS AND HYDROPHOBIC CONSTITUENTS, METHOD FOR PREPARING SAME, HYDRATED LIPID LAMELLAR PHASES AND MANUFACTURING METHOD, PHARMACEUTICAL OR COSMETIC COMPOSITIONS COMPRISING HYDRATED LAMID PHASES
FR2534487B1 (en) 1982-10-15 1988-06-10 Dior Christian Parfums METHOD FOR THE HOMOGENEIZATION OF HYDRATED LIPIDAL LAMELLAR PHASE DISPERSIONS, AND SUSPENSIONS OBTAINED THEREBY
US5162217A (en) 1984-08-27 1992-11-10 Bio-Technology General Corp. Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof
US6103243A (en) * 1985-05-15 2000-08-15 Biotechnology Australia Pty, Ltd Oral vaccines
US5256648A (en) * 1988-01-21 1993-10-26 Yale University Selective inhibition of gene expression by photoactivatable oligonucleotides
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5173397A (en) 1989-03-28 1992-12-22 Mitsubishi Paper Mills Limited Photographic support with titanium dioxide pigmented polyolefin layer
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5976789A (en) 1991-07-17 1999-11-02 Bio Merieux System of probes enabling HLA-DR typing to be performed, and typing method using said probes
WO1993009788A1 (en) 1991-11-13 1993-05-27 Baylor College Of Medicine Triplex forming oligonucleotide reagents targeted to the neu oncogene promoter and method of use
EP0592626B1 (en) 1992-03-11 2003-01-29 Dana-Farber Cancer Institute, Inc. METHODS TO CLONE mRNA
CA2134670A1 (en) 1992-04-30 1993-11-11 Dennis R. Roop Constitutive and inducible epidermal vector systems
US6007989A (en) 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US5686306A (en) * 1992-05-13 1997-11-11 Board Of Regents, The University Of Texas System Methods and reagents for lengthening telomeres
US5645986A (en) 1992-05-13 1997-07-08 Board Of Reagents, The University Of Texas System Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5470577A (en) 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
GB9318751D0 (en) 1993-09-09 1993-10-27 Health Lab Service Board Detection and speciation of campylobacter
DE4331012A1 (en) 1993-09-13 1995-03-16 Bayer Ag Nucleic acid-binding oligomers with N-branching for therapy and diagnostics
DK0724587T3 (en) 1993-09-29 2003-01-06 Nabi Nucleosides and nucleotides with enlarged rings
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) * 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
CA2202511A1 (en) 1994-10-12 1996-04-25 Laurence A. Roth Targeted delivery via biodegradable polymers
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
FI100556B (en) * 1995-03-01 1997-12-31 Biohit Oyj Procedure for Detecting Anti-DNA Antibodies, Diagnostic Procedure, Reagent Packaging and Autoimmune Disease Drugs
US5858987A (en) 1995-05-05 1999-01-12 Mitotix, Inc. E6AP antisense constructs and methods of use
US6147056A (en) * 1995-06-06 2000-11-14 Trustees Of Boston University Use of locally applied DNA fragments
US7094766B1 (en) * 1995-06-06 2006-08-22 Trustees Of Boston University Use of locally applied DNA fragments
US5955059A (en) * 1995-06-06 1999-09-21 Trustees Of Boston University Use of locally applied DNA fragments
US5733730A (en) 1995-08-25 1998-03-31 The Rockefeller University Telomere repeat binding factor and diagnostic and therapeutic use thereof
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
US5917019A (en) 1997-02-13 1999-06-29 The Rockefeller University Altered telomere repeat binding factor 2
AU8492398A (en) 1997-07-17 1999-02-10 Board Of Regents Of The University Of Nebraska, The Telomere mimetic compounds and methods of use for same
US5998175A (en) * 1998-07-24 1999-12-07 Lumigen, Inc. Methods of synthesizing and amplifying polynucleotides by ligation of multiple oligomers
US6130088A (en) * 1999-07-20 2000-10-10 Isis Pharmaceuticals Inc. Antisense modulation of telomeric repeat binding factor 1 expression
EP1992634A1 (en) 1999-09-10 2008-11-19 Geron Corporation Oligonucleotide n3'- p5' thiophosphoramidates: their synthesis and use
US6140125A (en) * 1999-10-15 2000-10-31 Isis Pharmaceuticals Inc. Antisense inhibition of bcl-6 expression
JP2001142181A (en) 1999-11-10 2001-05-25 Fuji Photo Film Co Ltd Silver halide color reversal photographic sensitive material and color image forming method using same
AU2001251115A1 (en) * 2000-03-31 2001-10-15 Trustees Of Boston University Use of locally applied dna fragments
US7358040B2 (en) * 2001-08-01 2008-04-15 Rigel Pharmaceuticals, Incorporated MRE 11: modulation of cellular proliferation
US7200531B2 (en) * 2001-08-17 2007-04-03 Bionicrie Life Sciences, Inc. Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides

Also Published As

Publication number Publication date
WO2001074342A3 (en) 2002-03-28
EP2363133A1 (en) 2011-09-07
WO2001074342A2 (en) 2001-10-11
US20030032611A1 (en) 2003-02-13
US20060183704A1 (en) 2006-08-17
HK1054184A1 (en) 2003-11-21
US7033829B2 (en) 2006-04-25
EP1274410A2 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
EP1247815A3 (en) Modified oligonucleotides and uses thereof
AU2001278142A1 (en) Common application metamodel including c/c++ metamodel
AU2002223827A1 (en) Well treatment
AU2001210146A1 (en) Determination of deformation of surgical tools
AU2001294549A1 (en) Process and intermediates
AU2733200A (en) Dna mobility modifier
AU2002224553A1 (en) Human proteases
AU2001251115A1 (en) Use of locally applied dna fragments
AU2002231206A1 (en) Treatment of depression
AU2001266225A1 (en) Decondensation of dna
AU2001288972A1 (en) Antipsychotic sulfonamide-heterocycles, and methods of use thereof
GB9906758D0 (en) Use of locally applied dna fragments
AU2001245414A1 (en) Treatment of allergies
WO2001098454A8 (en) Human dna sequences
AU2002211373A1 (en) Haplotypes of the por gene
AU2001285155A1 (en) Polymorphic dna fragments and uses thereof
AU2001256161A1 (en) Nail
AU2002221222A1 (en) Novel method and use
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AU2001253560A1 (en) Methods of treatment
AU2002221484A1 (en) Swab unit
AU2002347346A1 (en) Dna vaccine
AU2002329425A1 (en) Dna sequencer
AU2001240017A1 (en) Human enzyme molecules
AUPR282501A0 (en) Expression facilitating nucleotides